China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the injectable polycaprolactone-based dermal filler Ellansé M has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for the company as it seeks to expand its presence in the aesthetic medicine market in China.
Ellansé M: Innovative Dermal Filler Technology
Ellansé M is a Category III medical device product that leverages advanced technology to provide both instant correction and long-lasting rejuvenation. The product utilizes polycaprolactone (PCL) microspheres suspended in a carboxymethyl cellulose (CMC) carrier gel. This unique formulation ensures immediate volume restoration while promoting collagen production for sustained results. Both PCL and CMC have an excellent biocompatibility profile, making Ellansé M a safe and effective option for aesthetic treatments.
Diverse Product Range and Global Presence
Huadong Medicine’s Ellansé product line includes four dermal filler options: Ellansé™-S, Ellansé™-M, Ellansé™-L, and Ellansé™-E. These products differ only in their duration of performance, ranging from 12 months to up to 4 years. Ellansé has been registered in over 60 countries and regions worldwide and has been used clinically for 15 years. The acceptance of the Ellansé M filing by the NMPA highlights Huadong Medicine’s commitment to bringing innovative and effective aesthetic solutions to the global market.-Fineline Info & Tech
